Related Experiment Videos
Statin use in Canadians: trends, determinants and persistence
C Ineke Neutel1, Howard Morrison, Norm R C Campbell
1Centre for Chronic Diseases Prevention and Control, Public Health Agency of Canada, Ottawa, ON.
Summary
Statin use increased in Canada from 1994-2002, but many high-risk patients, including those with cardiovascular disease (CVD), still underuse these cholesterol-lowering medications. Improving statin adherence for at-risk populations is a priority.
Area of Science:
- Public Health
- Cardiovascular Health
- Pharmacology
Background:
- Regular statin use is crucial for managing chronic diseases like cardiovascular disease (CVD) by lowering cholesterol.
- This study examines statin utilization patterns in Canada, considering comorbidities and lifestyle factors.
Purpose of the Study:
- To describe statin use in Canada based on comorbidities and lifestyle risk factors.
- To determine persistence rates among Canadian statin users.
Main Methods:
- Utilized data from the longitudinal National Population Health Survey (1994-2002) with 8,198 respondents.
- Collected information on demographics, medication use, CVD risk factors, CVD, diabetes, and hypertension.
- Analyzed five interviews conducted at two-year intervals.
Main Results:
- Statin use increased significantly from 1.6% to 7.8% between 1994 and 2002.
- Higher statin use was observed with increased age, diabetes, BMI, physician visits, and prescription medication insurance.
- Despite increases, only 32.7% of heart patients used statins by 2002, indicating underuse in high-risk groups. Persistence was 74.6% among users from 2000-2002.
Conclusions:
- Statin use has risen and is associated with CVD and diabetes, yet significant underuse persists among high-risk individuals.
- Efforts to increase statin use in high-risk populations are a priority for healthcare professionals.
- Factors like education level influenced statin persistence.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...